A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification-Reference-Cited by-同舟云学术

A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification

Published:2017-02 Issue:1 Volume:44 Page:24-33
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Boisdron-Celle Michèle,Metges Jean Philippe,Capitain Olivier,Adenis Antoine,Raoul Jean Luc,Lecomte Thierry,Lam You Heng,Faroux Roger,Masliah Claude,Poirier Anne Lise,Berger Virginie,Morel Alain,Gamelin Erick

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference42 articles.

1. Treatment recommendations for metastatic colorectal cancer;etAranda;Clin Transl Oncol,2011

2. Colorectal cancer;Cunningham;Lancet,2010

3. Curative strategies for liver metastases from colorectal cancer: a review;Zdenkowski;Oncologist,2012

4. Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer;Saif;World J Gastroenterol,2009

5. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial;Ychou;Ann Surg Oncol,2013

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety;Pharmacogenomics;2023-06

2. The past, present, and future of chemotherapy with a focus on individualization of drug dosing;Journal of Controlled Release;2022-12

3. Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review;FARM HOSP;2022

4. A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing;British Journal of Cancer;2022-03-19

5. Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study;Journal of Personalized Medicine;2022-02-02